Top 10 Life Science Startup Investors in Norway in May 2025
A list of 10 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Norway. We rank investors based on the number of investments they made in Life science companies from Norway. We update this investor list every month.Top 10 Life Science Startup Investors in Norway in May 2025
Investor | Life Science Norway investments |
---|---|
Investinor | 2 |
World Wildlife Fund | 1 |
The Index Project | 1 |
Dynamk Capital | 1 |
Canica | 1 |
Nordic Impact | 1 |
Project Sandwater | 1 |
Birk Venture | 1 |
Bakken & Baeck | 1 |
Hadean Ventures | 1 |
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more
Investment focus
- Software, Biotechnology, Manufacturing
- Funding Round, Seed, Series A
- Norway, United States, Switzerland
Portfolio highlights
- Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
- Ignite — A powerful & easy spend management tool to accelerate your procurement success by bringing clarity, clean data & sophisticated analytics to your fingertips
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.
Show more
Investment focus
- Seafood, Food Processing, Farming
- Seed, Series A, Funding Round
- Norway, Faroe Islands, United Kingdom
Portfolio highlights
- OCEANIUM — OCEANIUM is a world-leading developer of innovative, functional seaweed ingredients to catalyse the seaweed industry for People Health and Ocean Health.
- Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
- Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.
Design to improve life is about solving real problems, small and large, simple and complex, systemic and emerging and is a life-long pursuit. The Index Project is a call to action. Are you in?
Show more
Investment focus
- Artificial Intelligence, Chemical, SaaS
- Seed, Series A, Series B
- United States, Denmark, Chile
Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Seed, Series B
- United States, Canada, Norway
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
- Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.
Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.
Show more
Investment focus
- Beauty, Medical, Biotechnology
- Private Equity, Series A, Series D
- Norway, Denmark, Switzerland
Portfolio highlights
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
- Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.
Show more
Investment focus
- Chemical, Life Science, Visual Search
- Seed
- Norway
Portfolio highlights
- Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.
Project Sandwater is a fresh take on venture investments within the Nordics and beyond.
Show more
Investment focus
- Medical, Consulting, Life Science
- Series A
- Norway, The Netherlands
Portfolio highlights
- Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Seed, Series A, Funding Round
- Norway, United Kingdom
Portfolio highlights
- APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
- Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
- Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.
Since 2011, we have built products with some of the most ambitious companies out there. From defining future homes with IKEA to building decentralised platforms with Coinbase.
Show more
Investment focus
- Chemical, Software, Life Science
- Seed, Angel
- Norway
Portfolio highlights
- Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
- Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region.
The funds are backed by leading private and institutional investors.
Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Sweden, Norway, Austria
Portfolio highlights
- SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
Investors by industry
Impact
Biotech
Gaming
FinTech
Google
Energy
Proptech
Marketplace
Consumer
Hardware
Artificial intelligence
Health Care
Climate
Community
EdTech
Sustainability
Venture Capital
Clean Energy
Real Estate
Financial Services
Video Games
B2B
Education
Publishing
Finance
Food and Beverage
Beauty
Infrastructure
Web3
Photography
Retail
Big Data
Organic Food
Payments
Social Media
Medical
Internet
Manufacturing
eSports
Construction
Digital Media
Art
Local
Sports
Music
Enterprise Software
Social Network
Wellness
Email
Franchise
Android
Mobile
Legal
Mobile Advertising
Platforms
Cannabis
Hospitality
Biotechnology
Travel
Fitness
Recruiting
Automotive
Medical Device
Social
Crowdfunding
Wine And Spirits
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Film
Life Science
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Celebrity
Software
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Germany
India
United States
Ireland
South Korea
Canada
Australia
New Zealand
Middle East
Oceania
Europe
Asia
South Africa
Armenia
Brazil
Qatar
Indonesia
Spain
China
Saudi Arabia
Sri Lanka
Vietnam
Africa
LATAM
Japan
Singapore
Finland
Estonia
Hungary
Ethiopia
Hong Kong
Georgia
Egypt
Ecuador
Denmark
France
Faroe Islands
Ghana
Croatia
Gibraltar
Bulgaria
Chile
Belize
Barbados
Costa Rica
Mali
Greece
Mexico
Liberia
Israel
Philippines
Malaysia
Italy
Lithuania
Liechtenstein
Kuwait
Norway
Morocco
Myanmar
Lebanon
Mauritius
Peru
Jersey
Panama
Malta
Nicaragua
Sweden
El Salvador
Uruguay
Portugal
Zambia
Ukraine
Uzbekistan
Senegal
Seychelles
Venezuela
Tajikistan
Taiwan
Serbia
Uganda
Sierra Leone
Turkey
Thailand
Tunisia
San Marino
Rwanda
Puerto Rico
Poland
Russian Federation
Tanzania
Slovenia
Zimbabwe
Togo
Dominican Republic
Azerbaijan
Nigeria
Bahamas
Namibia
Iceland
Iraq
United Arab Emirates
Jamaica
Honduras
Isle of Man
Bolivia
Luxembourg
Albania
Pakistan
Belgium
Grenada
Bahrain
Romania
Jordan
Argentina
Bangladesh
Belarus
Bermuda
Czech Republic
Algeria
Kazakhstan
Kenya
Cayman Islands
Cambodia
Austria
Oman
Cyprus
Latvia
Cameroon
Switzerland
Colombia
Guatemala
Marshall Islands
Investors in Norway by industry
Clean Energy
Transportation
Financial Services
Cryptocurrency
Big Data
Payments
Medical
Social Network
Medical Device
Internet
Social Media
Manufacturing
Blockchain
Construction
Software
Enterprise Software
Sports
CleanTech
Travel
EdTech
FinTech
Biotechnology
Consumer
Health Care
Climate
Sustainability
Mobile
Energy
Proptech
Impact
SaaS
Marketplace
Artificial intelligence
Community
Hardware
Gaming
Retail
Social
Fashion
Web3
B2B
Life Science
Publishing
Education
Oil and Gas
Renewable Energy
Music
Enterprise
Video Games
Biotech
Food and Beverage
Real Estate
Finance
Digital Media
Media (entertainment)
Agriculture (agtech)
Machine Learning